Meeting of the Advisory Committee; Meeting

• Published date: 23 June 2021
• Citation: 86 FR 32976
• Record Number: 2021-13174
• Section: Notices
• Court: Joint Board For The Enrollment Of Actuaries

32976

Federal Register / Vol. 86, No. 118 / Wednesday, June 23, 2021 / Notices

comments received will be provided to

the Council.

Public Disclosure of Comments:

Before including your address, phone

number, email address, or other

personal identifying information in your

comment, you should be aware that

your entire comment—including your

personal identifying information—may

be made publicly available at any time.

While you can ask us in your comment

to withhold your personal identifying

information from public review, we

cannot guarantee that we will be able to

do so.

Detailed Council meeting minutes

will be maintained in the Green River

District Office and will be available for

public inspection and reproduction

during regular business hours within 90

days following each meeting. Minutes

will also be posted to the Council web

page.

Authority: 43 CFR 1784.4–2.

Gregory Sheehan,

State Director.

[FR Doc. 2021–13112 Filed 6–22–21; 8:45 am]

BILLING CODE 4310–DQ–P

JOINT BOARD FOR THE

ENROLLMENT OF ACTUARIES

Meeting of the Advisory Committee;

Meeting

AGENCY

: Joint Board for the Enrollment

of Actuaries.

ACTION

: Notice of federal advisory

committee meeting.

SUMMARY

: The Joint Board for the

Enrollment of Actuaries gives notice of

a teleconference meeting of the

Advisory Committee on Actuarial

Examinations (a portion of which will

be open to the public) on July 8 and 9,

2021.

DATES

: Thursday, July 8, 2021, from 9:00

a.m. to 5:00 p.m. (EDT), and Friday, July

9, 2021, from 8:30 a.m. to 5:00 p.m.

(EDT).

ADDRESSES

: The meeting will be held by

teleconference.

FOR FURTHER INFORMATION CONTACT

: Ms.

Elizabeth Van Osten, Designated Federal

Officer, Advisory Committee on

Actuarial Examinations, at (202) 317–

3648 or Elizabeth.j.vanosten@irs.gov.

SUPPLEMENTARY INFORMATION

: Notice is

hereby given that the Advisory

Committee on Actuarial Examinations

will meet by teleconference on

Thursday, July 8, 2021, from 9:00 a.m.

to 5:00 p.m. (EDT), and Friday, July 9,

2021, from 8:30 a.m. to 5:00 p.m. (EDT).

The purpose of the meeting is to

discuss topics and questions that may

be recommended for inclusion on future

Joint Board examinations in actuarial

mathematics and methodology referred

to in 29 U.S.C. 1242(a)(1)(B) and to

review the May 2021 Pension (EA–2L)

and Basic (EA–1) Examinations in order

to make recommendations relative

thereto, including the minimum

acceptable pass scores. Topics for

inclusion on the syllabus for the Joint

Board’s examination program for the

November 2021 Pension (EA–2F)

Examination will be discussed.

A determination has been made as

required by section 10(d) of the Federal

Advisory Committee Act, 5 U.S.C. App.,

that the portions of the meeting dealing

with the discussion of questions that

may appear on the Joint Board’s

examinations and the review of the May

2021 EA–2L and EA–1 Examinations

fall within the exceptions to the open

meeting requirement set forth in 5

U.S.C. 552b(c)(9)(B), and that the public

interest requires that such portions be

closed to public participation.

The portion of the meeting dealing

with the discussion of the other topics

will commence at 1:00 p.m. (EDT) on

July 8, 2021, and will continue for as

long as necessary to complete the

discussion, but not beyond 3:00 p.m.

(EDT). Time permitting, after the close

of this discussion by Committee

members, interested persons may make

statements germane to this subject.

Persons wishing to make oral statements

should contact the Designated Federal

Officer at NHQJBEA@IRS.GOV and

include the written text or outline of

comments they propose to make orally.

Such comments will be limited to 10

minutes in length. Persons who wish to

attend the public session should contact

the Designated Federal Officer at

NHQJBEA@IRS.GOV to obtain

teleconference access instructions.

Notifications of intent to make an oral

statement or to attend the meeting must

be sent electronically to the Designated

Federal Officer by no later than July 1,

2021. In addition, any interested person

may file a written statement for

consideration by the Joint Board and the

Advisory Committee by sending it to

NQJBEA@IRS.GOV.

Dated: June 17, 2021.

Thomas V. Curtin, Jr.,

Executive Director, Joint Board for the

Enrollment of Actuaries.

[FR Doc. 2021–13174 Filed 6–22–21; 8:45 am]

BILLING CODE 4830–01–P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA–856]

Bulk Manufacturer of Controlled

Substances Application: Purisys, LLC.

AGENCY

: Drug Enforcement

Administration, Justice.

ACTION

: Notice of application.

SUMMARY

: Purisys, LLC. has applied to

be registered as a bulk manufacturer of

basic class(es) of controlled

substance(s). Refer to Supplemental

Information listed below for further

drug information.

DATES

: Registered bulk manufacturers of

the affected basic class(es), and

applicants therefore, may file written

comments on or objections to the

issuance of the proposed registration on

or before August 23, 2021. Such persons

may also file a written request for a

hearing on the application on or before

August 23, 2021.

ADDRESSES

: Written comments should

be sent to: Drug Enforcement

Administration, Attention: DEA Federal

Register Representative/DPW, 8701

Morrissette Drive, Springfield, Virginia

22152.

SUPPLEMENTARY INFORMATION

: In

accordance with 21 CFR 1301.33(a), this

is notice that on March, 12, 2021,

Purisys, LLC., 1550 Olympic Drive,

Athens, Georgia 30601–1602, applied to

be registered as a bulk manufacturer of

the following basic class(es) of

controlled substance(s):

Controlled substance Drug

code Schedule

3,4-

Methylenedioxyamphet-

amine.

7400 I

3,4-

Methylenedioxymetha-

mphetamine.

7404 I

3,4-Methylenedioxy-N-

ethylamphetamine. 7405 I

Psilocybin ........................ 7437 I

Psilocyn ........................... 7438 I

The company plans to bulk

manufacture the listed controlled

substances for the internal use

intermediates or for sale to its

customers. The company plans to

manufacture the above-listed controlled

substances as clinical trial and starting

materials to make compounds for

distribution to its customers. No other

VerDate Sep<11>2014 17:13 Jun 22, 2021 Jkt 253001 PO 00000 Frm 00095 Fmt 4703 Sfmt 4703 E:\FR\FM\23JNN1.SGM 23JNN1

jbell on DSKJLSW7X2PROD with NOTICES